Search | Clinical Trials Finder

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Nitazoxanide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Months to 16 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: St. Petersburg, Florida • New Orleans, Louisiana • Great Neck, New York + 4 more

Conditions: Opiate Dependence, HIV Infections
Interventions: Integrating drug treatment into HIV services; Behavioral
Lead sponsor: Organization to Achieve Solutions in Substance Abuse (OASIS); Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Oakland, California • San Leandro, California

Conditions: HIV, Acute HIV Infection
Interventions: Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV-1 Infection
Interventions: Lenacapavir, Placebo, B/F/TAF, TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Sacramento, California • Torrance, California + 7 more

Conditions: Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions: Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions: ARTAS Adapted Patient Navigation, Adherence Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 446 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: HIV/AIDS
Interventions: Prize-linked savings; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Domestic Violence, Sexually Transmitted Diseases
Interventions: Motivational interviewing to reduce risk for HIV and DV; Behavioral
Lead sponsor: Multnomah County Health Department; Government
Eligibility: 18 Years and older · Female only
Enrollment: 530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Reduction in behaviors capable of sexually transmitting HIV; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 8
States / cities: Denver, Colorado • Minneapolis, Minnesota • St Louis, Missouri + 2 more

Conditions: HIV, Peripheral Neuropathy
Interventions: Alpha-Lipoic Acid; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Maximal Control, Instrumental and Empowering, Minimal Control, Instrumental, Empowering; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 35 Years
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zidovudine, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: PrEP Uptake
Interventions: Motivational interviewing (MI), Standard-of-care; Behavioral · Other
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV -1 Infection, HIV Infections
Interventions: PRO 140 (humanized monoclonal antibody to CCR5), Placebo Comparator; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: HIV Infections
Interventions: Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV
Interventions: 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ridgefield, Connecticut

Conditions: HIV Infections
Interventions: Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more

Search by objective public record fields.

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children

Integrating Buprenorphine Into HIV Treatment

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Integrated HIV Prevention and HCV Care for PWID

Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya

Reducing HIV & Domestic Violence Risk in Women Offenders

Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)

Painful HIV Neuropathy and Alpha-Lipoic Acid

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

A Prospective Double-Blind Study of Retrovir in Early HIV Infection

Selective Exposure in HIV Prevention

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

MI-based PrEP Intervention

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

Daclizumab to Treat HIV-Infected Patients

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People